Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2015-02-03 | saposin C | Bexion Pharmaceuticals (USA - KY) | glioblastoma multiforme |
Granting of the orphan status in the US |
2016-05-30 | rovalpituzumab tesirine | Stemcentrx (USA - CA)/Aceso Biologics Consulting (UK) | small cell lung cancer |
Granting of the orphan status in the EU |
2015-11-25 | temozolomide | AmpliPharm Pharmaceuticals (USA - GA) | glioblastoma multiforme in pediatric patients |
Granting of the orphan status in the US |
2015-11-09 | 3-{3-[4-(1-aminocyclobutyl)phenyl]-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl}cpyridin-2-amine bis-mesylate | ARQ 092 | Proteus syndrome |
Granting of the orphan status in the US |
2018-01-08 | ocrelizumab | Genentech, a member of Roche Group (USA - CA - Switzerland) |
|
Granting of a Market Authorisation in the EU |
2017-05-01 | durvalumab | AstraZeneca (UK) | locally advanced or metastatic urothelial carcinoma | Granting of a Market Authorisation in the US |
2010-10-01 | 16-base single-stranded peptide nucleic acid oligonucleotide linked to a 7-amino acid peptide | Biogenera (Italy) | medulloblastoma |
Granting of the orphan status in the EU |
2016-01-11 | humanized IgG4 monoclonal antibody that binds human colony stimulating factor 1 receptor | Five Prime Therapeutics (USA - CA) | pigmented villonodular synovitis and tenosynovial giant cell tumor |
Granting of the orphan status in the US |
2017-07-20 | midostaurin | Novartis (Switzerland) |
|
Granting of a Market Authorisation in the EU |
2016-03-28 | maxacalcitol and betamethasone butyrate propionate | Chugai Pharmaceutical (Japan) Maruho (Japan) | psoriasis |
Granting of a Market Authorisation in Japan |
2016-03-21 | (S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)-imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)-benzamide | Acerta Pharma (USA - CA, The Netherlands), now AstraZeneca (UK) | chronic lymphocytic leukemia/small lymphocytic leukemia | Granting of the orphan status in the EU |
2016-03-21 | (S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)-imidazo[1,5-a]pyrazine-1-yl)-N-(pyridine-2-yl)-benzamide | Acerta Pharma (USA - CA, The Netherlands), now AstraZeneca (UK) | lymphoplasmacytic lymphoma | Granting of the orphan status in the EU |
2016-03-21 | valoctocogene roxaparvovec- adeno-associated viral vector serotype 5 containing a B-domain deleted variant of human coagulation factor VIII gene | Biomarin Pharmaceutical (USA - CA) | hemophilia A | Granting of the orphan status in the EU |
2016-03-21 | fenretinide | Clinipace (Germany) | cutaneous T-cell lymphoma |
Granting of the orphan status in the EU |
2016-03-21 | glucopyranosyl lipid A stable emulsion and recombinant NY-ESO-1 (New York esophageal squamous cell carcinoma-1) protein | Pharm Research Associates (UK) | soft tissue sarcoma | Granting of the orphan status in the EU |
2016-05-11 | florilglutamic acid (18F) | Piramal Imaging (India) | diagnosis of glioma | Granting of the orphan status in the US |
2016-03-21 | florilglutamic acid (18F) | Piramal Imaging (India) | diagnosis of hepatocellular carcinoma | Granting of the orphan status in the EU |
2016-03-21 | sindbis virus envelope pseudotyped lentiviral vector encoding NY-ESO-1 (New York esophageal squamous cell carcinoma-1) protein | Pharm Research Associates (UK) | soft tissue sarcoma |
Granting of the orphan status in the EU |
2016-03-21 | synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues | Alnylam Therapeutics (USA - MA) | primary hyperoxaluria |
Granting of the orphan status in the EU |
2016-03-21 | diaspirin cross-linked hemoglobin | New B Innovation (UK) | oesophageal cancer |
Granting of the orphan status in the EU |
© 2024 Biopharmanalyses - Powered by Samacom+